CUMYL-CB-MEGACLONE

CUMYL-CB-MEGACLONE is a synthetic cannabinoid that is also a new psychoactive substance (NPS). It was first identified in Slovenia in December 2019 and is sold as a designer drug.

Chemistry

CUMYL-CB-MEGACLONE is a derivative of CUMYL-PEGACLONE, which is itself a derivative of CUMYL-THPINACA. The structure of CUMYL-CB-MEGACLONE is characterized by a 1-amino-3,3-dimethyl-1-oxobutan-2-yl (ADB) group that is attached to the terminal carbon of the pentyl chain.

Pharmacology

The pharmacology of CUMYL-CB-MEGACLONE is not well understood. However, it is known to be a potent agonist of the CB1 receptor, which is the primary target of the psychoactive constituent in cannabis, Delta-9-tetrahydrocannabinol (THC).

Legality

CUMYL-CB-MEGACLONE is not currently listed in any schedule of the United Nations Drug Conventions, but it may be considered to be a controlled substance in some countries under analogue laws.

See also

• Synthetic cannabinoids
• New psychoactive substances
• CUMYL-PEGACLONE
• CUMYL-THPINACA

References

CUMYL-CB-MEGACLONE Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski